Navigation Links
Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study

* Glivec found to dramatically reduce the risk of cancer returning after surgery for Kit-positive gastrointestinal stromal tumors (GIST)

* Patients receiving placebo in this trial will now be offered Glivec

* Global regulatory submissions planned for use of Glivec as adjuvant therapy in GIST patients following surgery to remove primary tumor

* Glivec already approved as effective therapy for patients with advanced metastatic or inoperable Kit-positive GIST

BASEL, Switzerland, April 12, 2007 - Investigators will begin offering Glivec® (imatinib)[*] to patients receiving placebo in a major North American clinical trial after after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Glivec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

The interim analysis showed no recurrence of cancer in approximately 97% of patients given Glivec for a year after surgery to remove tumors, compared to approximately 83% of those who underwent surgery but received a placebo. The investigators made these results public because the study had met its primary endpoint in terms of the rate of recurrence-free survival.

The study involving more than 600 patients was sponsored by the National Cancer Institute (NCI), which is part of the US National Institutes of Health (NIH). It was conducted at multiple cancer centers in the US and Canada, and was led by the American College of Surgeons Oncology Group. Novartis supplied Glivec for use in the study, and also provided partial funding under a Cooperative Research and Development Agreement with NCI to support the clinical development of Glivec.

Glivec has already been confirmed as an effective therapy in its approved use for patients with advanced metastatic or unresectable (inoperable) Kit-positi
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:5/16/2008)...ata from three studies,evaluating associations bet...d the rate of blood transfusions, as well as the p...r erythropoiesis-stimulating agents (ESAs),in Medi...e presented at the,American Society of Clinical On... meeting will take place in Chicago from May 30 to...
(Date:5/16/2008)...ion of a Small Molecule with Dem...., May 16 /- Nektar,Therape...oday from a Phase 1,study of NKTR- 102, PEGylated ...activity in patients with refractory solid tumors....olecule PEGylation technology,produced an increase...
(Date:5/16/2008)...r Novel Approach to Blood ...wire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), an...el small,molecule therapeutics, announced today th...or Antagonist (DARA), showed statistically signifi... in patients with mild to,moderate hypertension. P...
(Date:5/15/2008)...- Eisai Corporation of North,America announced tod...out,compounds in the company,s oncology pipeline, ...h have been accepted for presentation at the,44th ... Oncology (ASCO),taking place in Chicago from May... on Eisai marketed products and,investigational co...
Breaking Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Hospital Launches Landmark Project in Emergency Medicine 9268 1Hospital Launches Landmark Project in Emergency Medicine 9268 2Hanger Orthopedic Group Inc Announces 2007 Year End Earnings Release Conference Call 9265 1Hanger Orthopedic Group Inc Announces 2007 Year End Earnings Release Conference Call 9265 2International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 1International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 2International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 3International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 4International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 5Other highlights in the Jan 8 JNCI 9262 1Other highlights in the Jan 8 JNCI 9262 2Other highlights in the Jan 8 JNCI 9262 3Other highlights in the Jan 8 JNCI 9262 4
...- CombinatoRx,Incorporated (NASDAQ: CRXX) today a...ed to its immuno-inflammatory product,candidates, ...t,Rheumatism (EULAR) Annual Congress of Rheumatolo... CRx-102 , In a poster entitled "Inhibition of Mac...CRx-102, a Novel Synergistic Combination,Drug Cand...
...bjective Sleep,Measures, MINNEAPOLIS, June 13, 200...ults presented today at SLEEP 2007, the 21st annua...ieties (APSS),VEC-162, a balanced melatonin (MT1/...rmaceuticals Inc. , demonstrated improvements,in o...d maintenance,in a Phase III trial of transient in...
Other Medicine Technology:Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 2Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 3Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 4Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo 2Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo 3Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo 4
(Date:5/16/2008)...o Save Vital Services for Frail Seniors and People...wswire-USNewswire/ -- Thousands of,homecare worker...warzenegger,s proposed cuts to hours of service, w...ornia,s most vulnerable workers and the,people the...these vital,services for seniors and people with d...
(Date:5/16/2008)...sents Urban Health Institute with 10,000 Sensual O...rg at Playboy Mansion Fundraiser, LOS ANGELES, Ma...ip-hop,and R & B artist J Kwon known best for his ...ll be presenting the Urban Health Institute (UHI) ... over $50,000. The donation is,being made to promo...
(Date:5/16/2008)...docs determine who would benefit most from chemo a... 16 (HealthDay News) -- A panel of 15 genes may he...mall cell lung cancer will experience a recurrence...y, a new study shows. , By extension, the same... less aggressive forms of the cancer who would be ...
(Date:5/16/2008)...TON, May 16 /PRNewswire-USNewswire/ -- As tropical...e Irrawaddy delta, survivors of,Cyclone Nargis are... Many,survivors still need assistance, as exposure... an increasingly dire situation., "The people liv...,recover from this disaster and get back on their ...
Breaking Medicine News(10 mins):Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2
...und a new cheek cell analysis which detects early ... inexpensive and early screening method for detect...cancer using buccal mucosa or cells scraped from t...rmation that separates patients with lung cancer f...
...s more likely to occur in patients who take high d...afety profile of non-steroidal anti-inflammatory d...bserved as early as three days after starting an i...ered to have one of the most favorable safety prof...
...the illnesses affecting man was generally known. I...versely affect sex life and the sperm quality in h...ntists led by Biochemist Koonakapalyam Ramasami Mu...onic alcoholism decreases the level of testosteron...
... country has strictly prohibited the import of chi...Myanmar to combat the ongoing was against Bird flu...tional border with Myanmar and there is frequently...order. Mr. C Sangnghina, The Director of State Ani...
Other Medicine News:Health News:Early Lung cancer detected by studying Cheek Cells 2
Pre-Loaded with a Stylet., ,Available Cuffed or Uncuffed, pre-loaded with a stylet to facilitate quick intubations.
Worlds 1st spray on medical gel lubricant, Sprayglyde was specifically designed to assist the insertion of laryngeal masks.
Pediatric Tracheal Tubes with Micro-thin-walled cuffs.
Indications For Usage: , Emergency use. , When medicant during ventilation is required.
Medicine Products: